Shanghai, China – 22 October, 2014 – La Fenice® Hypophyseal Hormone Infusion Pump ("La Fenice®"), an endocrinal management device of Shanghai MicroPort Medical (Group) Co ("MicroPort"), was recently awarded high-tech project by Science and Technology Commission of Shanghai Municipality.
La Fenice®, in-house developed by MicroPort's subsidiary Shanghai MicroPort Lifesciences Co, is designed for the treatment of Idiopathic Hypogonadotropic Hypogonadism ("IHH") which is also known as Kallmann Syndrome. In China, the incidence of IHH is 1/2000 in men and 1/10000 in women.
As the first domestically developed gonadotropin-releasing hormone ("GnRH") pulse pump, La Fenice® brings hope to many Chinese IHH patients. It works as an artificial hypothalamus – La Fenice® stimulates hypophysis to excrete follicle-stimulating hormone ("FSH") and luteinizing hormone ("LH") by simulating pulse excretion of human GnRH. In this way, it helps the development of the patient's secondary sex characters, enables him/her to regain sexuality and fertility, improves the bone mineral density and reduces the risk of cardiovascular diseases.
Currently, MicroPort has carried out clinical applications of our GnRH pulse pump in many influential hospitals across China.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.